Bausch Health Companies (BHC) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.77
- Estimate
- $1.24
- Surprise
- +42.5%
- Revenue (period 2026-09-30)
- $2.94B
- Score at report (before → after)
- 6.4 → 6.6/10
Revenue source: xbrl.
How the report landed
Bausch Health Companies (BHC) beat the $1.24 estimate with adjusted EPS of $1.77 — a large 42.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.4/10) to Hold at 6.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BHC Hold at 6.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +42.5% surprise compares with a +16.9% four-quarter average. Next scheduled report: 2027-02-17.
What supports the rating
- Strong earnings beat streak (3/4)
- Attractive valuation
What argues against it
- Concentration risk — Product: Xifaxan® (85.0%)
- Concentration risk — Product: Arestin® (95.0%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.73
- Stop
- $8.12
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
BHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $3.17B
- P/E (fwd)
- 2.0
- 52-week range
- $4.33–$9.04
- Off 52-week high
- 3.4%
- RSI (14)
- 47
- Volume vs avg
- 0.42×
- Score today
- 6.4/10